Followers | 2543 |
Posts | 250734 |
Boards Moderated | 34 |
Alias Born | 05/06/2014 |
Tuesday, December 20, 2022 1:01:37 PM
Source: GlobeNewswire Inc.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called TruvagaTM for customers residing in the United States. The new wellness product is offered through our new ecommerce site, www.truvaga.com, and promotes general wellbeing.
Truvaga is a handheld non-invasive vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve. Stress affects every aspect of our lives including sleep, memory, learning, weight, fitness and more. Truvaga offers a drug-free, simple, and convenient way to help reduce stress with just 2-minute sessions, day and night; no apps, batteries, chargers or phones are required.
“The launch of a wellness product is a tremendous step forward in our company’s strategy of making vagus nerve stimulation technology more accessible to people who can benefit from harnessing the power of the vagus nerve,” stated Dan Goldberger, Chief Executive Officer at electroCore. “The Truvaga product will allow customers to incorporate vagus nerve stimulation as part of a holistic approach to improving their wellbeing.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic company dedicated to improving outcomes through its non-invasive vagus nerve stimulation therapy platform. The Company is focused on the treatment of multiple conditions in neurology and product offerings promoting general wellbeing and human performance.
For more information, visit www.electrocore.com.
About TruvagaTM
Truvaga is a handheld vagus nerve stimulator that utilizes our proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better.
For more information, please visit www.truvaga.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
Primary Logo
Recent ECOR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:18:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:15:09 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/08/2024 08:06:39 PM
- electroCore Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:05:00 PM
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:04:51 PM
- Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- electroCore Announces the Launch of Truvaga Plus® for General Wellness • GlobeNewswire Inc. • 04/08/2024 12:30:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- electroCore Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- electroCore to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 • GlobeNewswire Inc. • 03/05/2024 09:05:00 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:00:51 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:16:30 PM
- electroCore Expands Intellectual Property Portfolio • GlobeNewswire Inc. • 12/26/2023 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 12/18/2023 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:15:26 PM
- electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/07/2023 12:53:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 11:11:39 AM
- Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023 • GlobeNewswire Inc. • 11/15/2023 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:16:36 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM